TY - JOUR
T1 - Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men
AU - Rhodes, Thomas
AU - Jacobson, Debra J.
AU - McGree, Michaela E.
AU - St. Sauver, Jennifer L.
AU - Sarma, Aruna V.
AU - Girman, Cynthia J.
AU - Lieber, Michael M.
AU - Klee, George G.
AU - Demissie, Kitaw
AU - Jacobsen, Steven J.
N1 - Funding Information:
Supported by Grants DK58859 , AR30582 and 1UL1 RR024150-01 from the Public Health Service , National Institutes of Health , National Cancer Institute Grant P50CA69568 and Merck Research Laboratories .
PY - 2012/1
Y1 - 2012/1
N2 - Purpose: We describe cross-sectional associations of benign prostate specific antigen with clinical urological measures and examined the risk of future urological outcomes in 2 population based cohorts of black and white men, respectively. Materials and Methods: Two population based cohort studies were established to characterize the natural history of and risk factors for prostate disease progression in white and black male residents of Olmsted County, Minnesota, and Genesee County, Michigan, respectively. Results: The benign prostate specific antigen distribution was similar in black men at a median of 32.9 pg/ml (25th, 75th percentiles 17.3, 68.0) and white men at a median of 32.2 pg/ml (25th, 75th percentiles 16.6, 68.9, respectively). However, it was much lower than in previous reports. For Olmsted County men in the upper quartile of benign prostate specific antigen there was a fifteenfold increased risk of prostate cancer (HR 14.6, 95% CI 3.168.6) and a twofold higher risk of treatment for benign prostatic hyperplasia (HR 2.2, 95% CI 1.24.2) after adjusting for age. After additional adjustment for baseline prostate specific antigen the association between benign prostate specific antigen and prostate cancer risk was attenuated but remained almost ninefold higher for men in the upper quartile of benign prostate specific antigen (HR 8.7, 95% CI 1.842.4). The twofold higher risk of treatment for benign prostatic hyperplasia also remained after adjusting for baseline prostate specific antigen for men in the upper benign prostate specific antigen quartile (HR 1.9, 95% CI 0.94.0). Conclusions: Results suggest that increased benign prostate specific antigen may help identify men with prostate cancer and those at risk for benign prostatic hyperplasia treatment.
AB - Purpose: We describe cross-sectional associations of benign prostate specific antigen with clinical urological measures and examined the risk of future urological outcomes in 2 population based cohorts of black and white men, respectively. Materials and Methods: Two population based cohort studies were established to characterize the natural history of and risk factors for prostate disease progression in white and black male residents of Olmsted County, Minnesota, and Genesee County, Michigan, respectively. Results: The benign prostate specific antigen distribution was similar in black men at a median of 32.9 pg/ml (25th, 75th percentiles 17.3, 68.0) and white men at a median of 32.2 pg/ml (25th, 75th percentiles 16.6, 68.9, respectively). However, it was much lower than in previous reports. For Olmsted County men in the upper quartile of benign prostate specific antigen there was a fifteenfold increased risk of prostate cancer (HR 14.6, 95% CI 3.168.6) and a twofold higher risk of treatment for benign prostatic hyperplasia (HR 2.2, 95% CI 1.24.2) after adjusting for age. After additional adjustment for baseline prostate specific antigen the association between benign prostate specific antigen and prostate cancer risk was attenuated but remained almost ninefold higher for men in the upper quartile of benign prostate specific antigen (HR 8.7, 95% CI 1.842.4). The twofold higher risk of treatment for benign prostatic hyperplasia also remained after adjusting for baseline prostate specific antigen for men in the upper benign prostate specific antigen quartile (HR 1.9, 95% CI 0.94.0). Conclusions: Results suggest that increased benign prostate specific antigen may help identify men with prostate cancer and those at risk for benign prostatic hyperplasia treatment.
KW - continental population groups
KW - prostate
KW - prostate-specific antigen
KW - prostatic hyperplasia
KW - prostatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=83555164654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83555164654&partnerID=8YFLogxK
U2 - 10.1016/j.juro.2011.09.061
DO - 10.1016/j.juro.2011.09.061
M3 - Article
C2 - 22093190
AN - SCOPUS:83555164654
SN - 0022-5347
VL - 187
SP - 87
EP - 91
JO - Investigative Urology
JF - Investigative Urology
IS - 1
ER -